Fallowfield, L. http://orcid.org/0000-0003-0577-4518
Solis-Trapala, I. http://orcid.org/0000-0002-1264-1396
Starkings, R. http://orcid.org/0000-0002-1947-018X
Catt, S. http://orcid.org/0000-0002-9898-2289
May, S. http://orcid.org/0000-0002-3167-9891
Jenkins, V. http://orcid.org/0000-0001-8939-0081
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-17-050)
Article History
Received: 3 April 2019
Accepted: 6 June 2019
First Online: 14 June 2019
Compliance with ethical standards
:
: LJF has received research grants from Bristol Myers Squibb, and from Novartis. LJF has received speaker honorarium from Amgen, TEVA, Voluntis, Oncolia, Pfizer, Eisai and Genomic Health and had a consultancy role with Puma Biotechnology, Roche, Eisai, Voluntis, AstraZeneca and Takeda. VAJ has received research grants from Aventis Pharma trading as Sanofi. All other authors have no conflicts of interest to declare.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards (ref: ER/RMLS21/1). The datasets during and/or analysed during the current study are available from the corresponding author on reasonable request